$1.05
-0.03 (-2.78%)
Open$1.09
Previous Close$1.08
Day High$1.11
Day Low$1.01
52W High$22.60
52W Low$0.95
Volume—
Avg Volume634.7K
Market Cap5.63M
P/E Ratio—
EPS$-5.21
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,827.6% upside
Current
$1.05
$1.05
Target
$20.24
$20.24
$14.74
$20.24 avg
$23.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.47M | 3.50M |
| Net Income | -124,680 | -125,666 | -103,892 |
| Profit Margin | -3.0% | -2.8% | -3.0% |
| EBITDA | -157,557 | -149,483 | -127,277 |
| Free Cash Flow | -89,797 | -95,523 | -91,369 |
| Rev Growth | +15.0% | +2.0% | +12.9% |
| Debt/Equity | 1.05 | 1.12 | 1.09 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |